Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI-Reference-Cited by-同舟云学术

Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI

Published:2019-06-25 Issue:24 Volume:321 Page:2414
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Watanabe Hirotoshi¹,Domei Takenori²,Morimoto Takeshi³,Natsuaki Masahiro⁴,Shiomi Hiroki¹,Toyota Toshiaki⁵,Ohya Masanobu⁶,Suwa Satoru⁷,Takagi Kensuke⁸,Nanasato Mamoru⁹,Hata Yoshiki¹⁰,Yagi Masahiro¹¹,Suematsu Nobuhiro¹²,Yokomatsu Takafumi¹³,Takamisawa Itaru¹⁴,Doi Masayuki¹⁵,Noda Toshiyuki¹⁶,Okayama Hideki¹⁷,Seino Yoshitane¹⁸,Tada Tomohisa¹⁹,Sakamoto Hiroki¹⁹,Hibi Kiyoshi²⁰,Abe Mitsuru²¹,Kawai Kazuya²²,Nakao Koichi²³,Ando Kenji²,Tanabe Kengo²⁴,Ikari Yuji²⁵,Hanaoka Keiichi Igarashi²⁶,Morino Yoshihiro²⁷,Kozuma Ken²⁸,Kadota Kazushige⁶,Furukawa Yutaka⁵,Nakagawa Yoshihisa²⁹,Kimura Takeshi¹,

Affiliation:

1. Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan

2. Department of Cardiology, Kokura Memorial Hospital, Kitakyusyu, Japan

3. Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan

4. Department of Cardiovascular Medicine, Saga University, Saga, Japan

5. Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan

6. Department of Cardiology, Kurashiki Central Hospital, Kurashiki, Japan

7. Department of Cardiology, Juntendo University Shizuoka Hospital, Izunokuni, Japan

8. Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan

9. Department of Cardiology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan

10. Department of Cardiology, Minamino Cardiovascular Hospital, Hachioji, Japan

11. Department of Cardiology, Sendai Cardiovascular Center, Sendai, Japan

12. Department of Cardiology, Saiseikai Fukuoka General Hospital, Fukuoka, Japan

13. Department of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan

14. Department of Cardiology, Sakakibara Heart Institute, Fuchu, Japan

15. Department of Cardiology, Kagawa Prefectural Central Hospital, Takamatsu, Japan

16. Department of Cardiology, Gifu Prefectural General Medical Center, Gifu, Japan

17. Department of Cardiology, Ehime Prefectural Central Hospital, Matsuyama, Japan

18. Department of Cardiology, Hoshi General Hospital, Koriyama, Japan

19. Department of Cardiology, Shizuoka General Hospital, Shizuoka, Japan

20. Division of Cardiology, Yokohama City University Medical Center, Yokohama, Japan

21. Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan

22. Department of Cardiology, Chikamori Hospital, Kochi, Japan

23. Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, Kumamoto, Japan

24. Department of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan

25. Department of Cardiology, Tokai University Hospital, Isehara, Japan

26. Hanaoka Seishu Memorial Cardiovascular Clinic, Sapporo, Japan

27. Department of Cardiology, Iwate Medical University Hospital, Morioka, Japan

28. Department of Cardiology, Teikyo University Hospital, Tokyo, Japan

29. Department of Cardiovascular Medicine, Shiga University of Medical Science, Otsu, Japan

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

http:///jama/article-pdf/321/24/2414/17671789/jama_watanabe_2019_oi_190060.pdf

Reference36 articles.

1. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery.;Levine;Circulation,2016

2. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).;Valgimigli;Eur Heart J,2018

3. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials.;Palmerini;Lancet,2015

4. Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: a comparison between the DAPT study and 9 other trials evaluating DAPT duration.;Toyota;PLoS One,2017

5. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.;Mauri;N Engl J Med,2014

Cited by 600 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence and outcomes of high bleeding risk patients with type 1 and type 2 myocardial infarction in a community-based cohort: Application of the Academic Research Consortium High Bleeding Risk Criteria;International Journal of Cardiology;2024-02

2. Second-generation everolimus-eluting intracoronary stents: a comprehensive review of the clinical evidence;Future Cardiology;2024-01-31

3. After placement of a newer-generation drug-eluting coronary artery stent in a patient with a high bleeding risk, does one month of dual antiplatelet therapy effectively reduce the incidence of major bleeding while also maintaining stent effectiveness?;Evidence-Based Practice;2024-01-25

4. Randomized evaluation of 5-month Ticagrelor monotherapy after 1-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with drug-coated balloons: REC-CAGEFREE II trial rationale and design;BMC Cardiovascular Disorders;2024-01-20

5. Aspirin-free antiplatelet strategies after percutaneous coronary interventions;European Heart Journal;2024-01-18